From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Transdermal Fentanyl for Severe Osteoarthritis

This opioid is a treatment option for patients with severe knee or hip osteoarthritis, but side effects are common.

Many patients with painful osteoarthritis cannot tolerate nonsteroidal anti-inflammatory drugs (NSAIDs), have contraindications to NSAIDs, or get inadequate pain relief from NSAIDs or acetaminophen. In this industry-sponsored international study, researchers examined the efficacy of opioid therapy with transdermal fentanyl for patients with moderate-to-severe pain caused by hip or knee osteoarthritis. All patients were thought to require joint replacement and were awaiting surgery, had refused surgery, or had medical contraindications to surgery.

About 400 patients were randomized to receive transdermal fentanyl patches (25 µg every 3 days, titrated to a maximum of 100 µg, if needed) or placebo patches. Only half of the patients completed the study: Fentanyl recipients were less likely than placebo recipients to withdraw because of lack of efficacy (7% vs. 33%) but were more likely to withdraw because of adverse events (27% vs. 10%). In an intent-to-treat analysis, pain relief was significantly greater in the fentanyl group than in the placebo group: The mean visual analog pain score (range, 0–100) decreased from 73 to 50 with fentanyl and from 73 to 55 with placebo.

Comment: These findings establish transdermal fentanyl as a treatment option for patients with severe knee or hip osteoarthritis. However, the average effect was not dramatic, owing to a substantial placebo effect and a high dropout rate because of side effects (especially nausea, vomiting, somnolence, and dizziness).

— Allan S. Brett, MD

Published in Journal Watch General Medicine July 4, 2006

Citation(s):

Langford R et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: A randomized, placebo-controlled trial. Arthritis Rheum 2006 Jun; 54:1829-37.

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2006. Massachusetts Medical Society. All rights reserved.